Dyne Therapeutics 40% Rally Faces Fund Selloff Questions
A dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
Understanding the financial goals you should have at 55 is vital for retirement planning. Explore key objectives to focus on for success.
27,702 articlesA dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
As Ethereum’s core stewardship rethinks its mission, Vitalik Buterin advocates a leaner, more opinionated foundation....
A clear look at how SiriusPoint may perform in 2025. This guide breaks down underwriting discipline, investment resul...
Ciena’s shares jumped sharply in the first half of 2026. This article dives into the AI-driven demand for optical net...
CoreWeave’s latest trading session highlighted the tension between high-growth AI clouds and the realities of funding...
A large holder trimmed a substantial stake in a biotech name while the stock advanced. This piece explains what inves...
Yield-focused investors have chased AMDY's eye-catching yield this options strategy promises. Yet the income is volat...
The market loves dramatic headlines about AI threatening legacy tech, but the real story is nuanced. This piece expla...
Stratasys is stepping into 2025 with a focused plan to diversify revenue, improve margins, and scale software-led ser...
A rare moment of optimism surrounds Uber as Dara Khosrowshahi signals a sharper focus on execution and profitability....
When a packaging company posts stronger results, investors take notice. This piece explains why karat packaging stock...
A high-growth, small-cap name has tumbled after a rough period. This guide breaks down whether the dip creates a real...